IP Veteran Joins BioSig Technologies’ Board of Directors

BioSig Technologies Inc., a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, has appointed Andrew Filler to its Board of Directors.
 
Filler brings to BioSig over 20 years of experience in intellectual property for technology and medical device companies. He currently serves as partner and general counsel for Sherpa Technology Group, a Silicon Valley IP advisory firm. Prior to this assignment, Filler served as vice president of IP for Nanosys Inc., where he created and managed one of the largest nanotechnology patent portfolios in the world with over 800 patents and applications. Under his leadership Nanosys completed hundreds of multi-million-dollar licensing, equity and collaborative agreements with companies such as Samsung, Intel, LG, and Medtronic. Filler was recently named as one of the top two corporate IP attorneys in Silicon Valley by the San Jose/Silicon Valley Business Journal in 2011 and previously served as chief intellectual property counsel at Caliper Technologies, senior associate attorney at Weil, Gotshal & Manges, and director of intellectual property at Corvascular. 
 
Filler is replacing Dr. Jerome B. Zeldis, former CEO of Celgene Global Health and chief medical officer of Celgene Corporation, who has served the BioSig shareholders since 2014 and is now retiring from board service.
 
“What unites all members of BioSig’s board is their confidence in the company’s ability to deliver on a very strong value proposition. I’m honored to join BioSig at this exciting time and contribute my knowledge and experience to further strengthen the company’s positioning as the emerging leader in biomedical signal processing,” said Filler.   
 
“The quality of our Board of Directors is our biggest asset. The guidance that each Board member has brought to the company throughout the years was, and remains, invaluable. As we progress towards commercialization, Andy’s deep understanding of technology and his legal background will be key components for shaping our future licensing and business development strategy,” said Kenneth Londoner, chairman and CEO of BioSig Technologies.

BioSig Technologies is a medical device company developing a proprietary biomedical signal processing technology designed to improve the $4.6 billion electrophysiology (EP) marketplace. The Los Angeles, Calif.-based firm is preparing to commercialize its PURE EP(TM) System, technology that has been developed to address an unmet need in a large and growing market. The PURE EP System is a cardiac signal acquisition and display system, which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, atrial fibrillation and ventricular tachycardia. BioSig has partnered with Minnetronix on technology development and is working toward U.S. Food and Drug Administration 510(k) clearance for the PURE EP System.